Please use this identifier to cite or link to this item:
|Title:||APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease.|
|Authors:||Lim, Yen Ying;Villemagne, Victor L;Pietrzak, Robert H;Ames, David;Ellis, Kathryn A;Harrington, Karra;Snyder, Peter J;Martins, Ralph N;Masters, Colin L;Rowe, Christopher C;Maruff, Paul|
|Institutional Author:||Australian Imaging, Biomarkers and Lifestyle (AIBL) Research Group|
|Affiliation:||Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australia|
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
Cogstate Ltd., Melbourne, Victoria, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Electronic address: firstname.lastname@example.org.
Department of Neurology, Rhode Island Hospital, Providence, RI, USA
Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
|Citation:||Neurobiology of Aging 2014; 36(3): 1239-44|
|Abstract:||The apolipoprotein E (APOE) ɛ4 allele and high levels of beta-amyloid (Aβ) are associated with episodic memory decline and risk for Alzheimer's disease. However, there is debate about independent or interactive effects of ɛ4 on Aβ-related memory decline in healthy older adults. Healthy older adults with high Aβ burden (n = 84) enrolled in Australian Imaging, Biomarkers, and Lifestyle Study were included in this study. Cognition was measured using the computerized Cogstate Brief Battery at baseline, 18-, 36-, and 54-month follow-ups. Mini Mental State Examination and Clinical Dementia Rating scales were also administered at baseline and each follow-up timepoint. Relative to Aβ+ ɛ4 noncarriers (n = 36), Aβ+ ɛ4 carriers (n = 48) showed significantly faster decline on memory tasks, which was by convention, moderate in magnitude (d = 0.40-0.47). Aβ positivity coupled with APOE ɛ4 was associated with moderately increased decline in memory over a 54-month assessment period, suggesting that, in the preclinical stages of Alzheimer's disease, the manifestation of memory decline in older adults with high Aβ is exacerbated by the presence of APOE ɛ4.|
|Internal ID Number:||25559335|
Preclinical Alzheimer's disease
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.